Safety and Efficacy of Seroquel in First Episode Schizophrenia

AstraZeneca

Status and phase: Completed; Phase 4

Conditions: Schizophrenia

Treatments: Drug: Seroquel and Risperidone

Study type: Interventional

Funder types: Industry

Identifiers

NCT00254241

BU-5077-0011

Details and patient eligibility

About

To compare the safety, tolerability and efficacy of Seroquel and risperidone in first episode schizophrenia

Sex: All

Ages: 18 to 35 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age 18-35 years Meet ICD-10 criteria for schizophrenia No abnormaility on clinical examination No previous episode of psychosis No previous antipsychotics of any kind in last 3 months

Exclusion criteria

• Have received a course of antipsychotics drug treatment prior to entry which may introduce risk factors or interfere with study procedures Have received anticholinergics within 10 days of baseline aseessment Have received mood stabilizers or anti depressants within 2 weeks

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind